Sign In
24 Apr 2014 07:00
24 April 2014
TyraTech, Inc.
("TyraTech" or the "Company")
USA patents for pest control compositions secured
TyraTech, Inc. (AIM: TYR and TYRU), a life sciences company focusing on nature-derived insect and parasite control products, is pleased to announce that the Company has received notice from the United States Patent and Trademark Office ("USPTO") granting two new patents for the Company's novel pest control compositions.
The first patent covers a range of current and pipeline animal health products, including those that will be sold by Novartis Animal Health US, Inc. for the control of flies, cockroaches and other insects in production animal facilities and premises. This patent also covers products sold into the professional pest control and commercial/institutional markets by Envance Technologies, LLC, which is TyraTech's joint venture with AMVAC Chemical Corporation. The patent has a 20-year term, which expires in 2027.
The second patent covers TyraTech's Extend™ technology, which harnesses the synergy between natural and synthetic compounds to achieve increased efficacy while reducing the environmental footprint of synthetic pesticides. This patent supports a number of the Company's animal health pipeline products, as well as pipeline products from Envance Technologies. The patent has a 20-year term, which expires in 2029.
The issuance of these patents raises TyraTech's patent portfolio to 21 granted United States and international patents protecting its proprietary screening platform and compositions. The Company currently has 50 United States and international patent applications pending.
Bruno Jactel, Chief Executive Officer, said: "These new patents are a testimony to the quality and innovation behind TyraTech's technology and products. More importantly they will provide protection for TyraTech's products that are already in the market and for products that TyraTech is currently developing. Our research and development teams are continually working to develop new products and formulations that are patentable with the objective of strengthening our growth platform."
For further information please contact:
TyraTech Inc.Alan Reade, Non-Executive Chairman Tel: +44 78 4197 8709Bruno Jactel, Chief Executive Officer Tel: +1 919 415 4340 | |
SPARK Advisory Partners Limited, Nominated Adviser Matt Davis / Mark Brady Tel: +44 20 3368 3551
Allenby Capital Limited, Joint Broker Chris Crawford Tel: +44 20 3328 5656
|
|
Whitman Howard, Joint Broker Ranald McGregor-Smith/ Niall Devins Tel: 44 20 7087 4550
Walbrook, Financial PR and IRBob Huxford /Guy McDougall (Public Relations) Tel: +44 20 7933 8792Paul Cornelius (Investor Relations) Tel: +44 20 7933 8794 | |
Follow the stocks
